BrainBase SIGNED
Knowledge management platform for clinical use of brain data
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0BrainBase project word cloud
Explore the words cloud of the BrainBase project. It provides you a very rough idea of what is the project "BrainBase" about.
Project "BrainBase" data sheet
The following table provides information about the project.
| Coordinator |
BIOMAX INFORMATICS AG
Organization address contact info |
| Coordinator Country | Germany [DE] |
| Project website | https://www.biomax.com/solution/brain-science/ |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-1 |
| Funding Scheme | SME-1 |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-09-01 to 2019-02-28 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | BIOMAX INFORMATICS AG | DE (PLANEGG) | coordinator | 50˙000.00 |
Map
Project objective
The connectome is a map of all neural connections in the brain that can provide information about the brain’s (re)wiring in neurological diseases, injuries, or drugs responses. The use of connectomes in clinical practice has enormous potential to improve treatment efficacy, enhance patient stratification, disease characterization, and ultimately diagnosis. However, the means to clinically utilize connectomes are limited. Therefore neurologists still rely on subjective analysis of brain scans. Although the use of big data tools in neuro-diagnostics is growing, no commercial application for clinical practice is available yet.
Biomax developed the first commercial solution to translate big connectome data into clinically relevant information: NeuroXM. In combination with patients’ clinical data this can be valorized to improve neuro-diagnosis. NeuroXM has successfully undergone pilot studies at two major institutes. The proprietary NeuroXM platform includes all features and security levels that are required in the clinic. Biomax is a strong bioinformatic SME with 20 years’ experience, including >25 European grants, 5 successful bioinformatic products, and a pioneering reputation.
NeuroXM targets a very large and diverse neurology market with multiple clinical applications, e.g. diagnosis of dementia using brain imaging, detecting brain wiring “disconnections” in schizophrenia, and establishing treatment efficacy (longitudinal assessments of the connectome). This SME Phase 1 project will assess the feasibility of these different applications, which will help Biomax to establish a Go/No-go for further clinical validation for the specific clinical applications. With a strong first mover advantage and freedom to operate, NeuroXM has the potential to become the gold standard for working with connectome data. Commercialization of NeuroXM will provide Biomax a cumulative revenue of €47,4 million (2025) and further company growth.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRAINBASE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "BRAINBASE" are provided by the European Opendata Portal: CORDIS opendata.